PF
LCTX icon

Phoenix Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Phoenix Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-48,716
Closed -$60.4K – 315
2022
Q4 		$60.4K Buy
48,716
+1,129
+2% +$1.42K ﹤0.01% 271
2022
Q3 		$55K Sell
47,587
-130,249
-73% -$191K ﹤0.01% 329
2022
Q2 		$282K Buy
177,836
+66,291
+59% +$87.4K 0.01% 328
2022
Q1 		$172K Sell
111,545
-12,321
-10% -$19.1K ﹤0.01% 391
2021
Q4 		$306K Buy
+123,866
New +$290K 0.01% 329

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Phoenix Financial's LCTX Position: Q1 2023 in Review

Phoenix Financial sold out of Lineage Cell Therapeutics (LCTX) in Q1 2023, closing a stake of 48,716 shares — an estimated $60.4K sold.

Phoenix Financial first reported a position in LCTX in Q4 2021 and held it in 5 quarters. The position peaked at $306K in Q4 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • Phoenix Financial reported no remaining Lineage Cell Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Phoenix Financial sold 48,716 Lineage Cell Therapeutics shares in Q1 2023, an estimated $60.4K.
  • Phoenix Financial first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 5 quarters.
  • Phoenix Financial's Lineage Cell Therapeutics position peaked at $306K in Q4 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on Phoenix Financial's 13F filing for Q1 2023, filed 11 May 2023.